Early Detection of Emerging SARS-CoV-2 Variants of Interest

2 for Experimental Evaluation

- 4 Zachary S. Wallace^{1,2}, James Davis^{3,4}, Anna Maria Niewiadomska¹, Robert D. Olson^{3,4}, Maulik Shukla^{3,4},
- 5 Rick Stevens^{5,6}, Yun Zhang¹, Christian M. Zmasek¹, Richard H. Scheuermann^{1,7,8,9*}
- ¹ Department of Informatics, J. Craig Venter Institute, La Jolla, CA, 92037, USA
- 8 ² Department of Computer Science and Engineering, University of California, San Diego, CA, 92039, USA
- ⁹ Division of Data Science and Learning, Argonne National Laboratory, Lemont, IL, USA
- 10 ⁴ University of Chicago Consortium for Advanced Science and Engineering, University of Chicago,
- 11 Chicago, IL, USA

1

3

6

17

21

22

- 12 ⁵ Computing Environment and Life Sciences, Argonne National Laboratory, Argonne, IL, 60439, USA
- 13 ⁶ Department of Computer Science, University of Chicago, Chicago, IL 60637, USA
- ⁷ Department of Pathology, University of California, San Diego, CA, 92093, USA
- 15 Bivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA
- 16 ⁹ Global Virus Network, Baltimore MD, 21201, USA
- 18 *Correspondence: Richard Scheuermann, rscheuermann@jcvi.org
- 19 Key Words: SARS-CoV-2, variants of concern, Omicron, Delta, viral evolution, genomic surveillance,
- 20 early detection, bioinformatics

Abstract

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

Since the beginning of the COVID-19 pandemic, SARS-CoV-2 has demonstrated its ability to rapidly and continuously evolve, leading to the emergence of thousands of different sequence variants, many with distinctive phenotypic properties. Fortunately, the broad availability of next generation sequencing (NGS) technologies across the globe has produced a wealth of SARS-CoV-2 genome sequences, offering a comprehensive picture of how this virus is evolving so that accurate diagnostics and reliable therapeutics for COVID-19 can be maintained. The millions of SARS-CoV-2 sequences deposited into genomic sequencing databases, including GenBank, BV-BRC, and GISAID are annotated with the dates and geographical regions of sample collection, and can be aligned to the Wuhan-Hu-1 reference genome to extract the constellation of nucleotide and amino acid substitutions. By aggregating these data into concise datasets, the spread of variants through space and time can be assessed. Variant tracking efforts have focused on the spike protein due to its critical role in viral tropism and antibody neutralization. To identify emerging variants of concern as early as possible, we developed a computational pipeline to process the genomic data from public databases and assign risk scores based on both epidemiological and functional parameters. Epidemiological dynamics are used to identify variants exhibiting substantial growth over time and across geographical regions. In addition, experimental data that quantify Spike protein regions critical for adaptive immunity are used to predict variants with consequential immunogenic or pathogenic impacts. These growth assessment and functional impact scores are combined to produce a Composite Score for any set of Spike substitutions detected. With this systematic approach to routinely score and rank emerging variants, we have established a method to identify threatening variants early and prioritize them for experimental evaluation.

Introduction

The ongoing evolution of SARS-CoV-2 has remained a persistent public heath challenge throughout the entire course of the pandemic. In just two and a half years since the first strain of the virus was isolated and fully sequenced, SARS-CoV-2 has evolved into hundreds of thousands of strains containing unique combinations of mutations, also known as variant constellations, with many of these mutations leading to altered virus phenotypes in terms of antigenicity, transmissibility, and viral fitness.^{25,26} In order to label the rapidly growing collection

58

59

60

61

62

63

64

65

66

67

68 69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

8788

of variants, the scientific community has relied on the PANGO Lineage²¹ nomenclature or WHO classifications as naming schemes for these variants. The continual emergence of SARS-CoV-2 variants has caused public health agencies to categorize these lineages depending on their predicted importance. In the United States, the CDC has identified these as four categories: Variants Being Monitored (VBM), Variants of Interest (VOI), Variants of Concern (VOC), or Variants of High Consequence (VOHC). Classification is dependent on viral growth dynamics and level of threat to preexisting immunity or therapeutic efficacy. Notable Variants of Concern include B.1.1.7 (WHO class Alpha), B.1.617.2 (WHO class Delta), and the most recent B.1.1.529/BA.1-BA.5 (WHO class Omicron).²⁷ It has been a consistent pattern throughout the course of the pandemic for SARS-CoV-2 to acquire genetic changes of functional and epidemiological importance, beginning with the observation as early as Spring 2020 that the Spike protein mutation, D614G, was associated with higher viral loads and was under positive selection. 16 Since then, with the emergence of Alpha and Delta, Spike mutations such as N439R, N501Y, E484K, and P681H, have been linked to increased ACE2 binding affinity, antibody binding escape, and enhanced viral replication. 3,29,32, The most recently emerged Variant of Concern, Omicron, has been reported to contain constellations of mutations across the n-terminal domain (NTD) and receptor binding domain (RBD). This has resulted in high levels of viral antigenic escape, and partial or complete resistance to the majority of available therapeutic monoclonal antibodies and, to a large extent, infection or vaccine-elicited polyclonal sera. 14,30 The astonishing ability of SARS-CoV-2 to rapidly evolve into variants with expanded cellular tropism, enhanced replication, increased transmissibility, and evasion of preexisting immunity has triggered the scientific community to band together and critically monitor the evolution of this virus through efforts like the US National Institute of Allergy and Infectious Diseases (NIAID)'s SARS-CoV-2 Assessment of Viral Evolution (SAVE) program¹ and COVID-19 Genomics UK Consortium (COG UK), which seek to iteratively provide a risk-assessment of emerging variants of interest and offer recommendations towards an optimal public health response. A key component to successfully monitoring viral evolution, and thereby setting the stage for risk assessment, is through genomic surveillance. 12,16 Thanks to the growing availability of next generation sequencing (NGS) technologies, SARS-CoV-2 genome sequences from millions of infected individuals across the globe have been determined and deposited into public databases¹¹ such as the National Center for Biotechnology Innovation (NCBI) GenBank, the Global Initiative on Sharing Avian Influenza Data (GISAID)²⁰, and the Bacterial and Viral

Bioinformatics Resource Center (BV-BRC)²⁴. These data have been dynamically growing at a rapid pace since the early stages of the pandemic and have allowed researchers to pinpoint mutations under positive or negative selection through the evaluation of occurrence rates of synonymous versus non-synonymous nucleotide substitutions or identify the mutational drivers of evolution by modeling growth as a linear combination of the effects of individual mutations. 15,31 Overall, the amount of SARS-CoV-2 genomic sequencing being carried out on a global scale and the bioinformatics capabilities to understand these data has opened opportunities for diverse research into strategies for the early detection of emerging variants of concern. This is a concept by which computational frameworks are used to manage and analyze rapidly growing viral sequencing data and ultimately prioritize emerging variants based on epidemiological dynamics and functional characteristics in near real time^{1,15,17}. The concept of early detection is a key aspect of the NIAID SAVE program - to select and prioritize the variants for in vitro and in vivo experimentation to assess risk of novel emerging variants (see Reference #1 for a complete description of the NIAID SAVE program for more details of the integrated workflow). Here we present a computational heuristic developed for early detection of SARS-CoV-2 emerging variants of interest, which combines spatiotemporal sequence prevalence dynamics and geographic spread with functional impact prediction, that can be used to rank variants composed of constellations of substitutions. The methods described have been used to rank emerging variants of interest for the NIAID SAVE consortium Early Detection group every month since early 2021 to inform wet-lab experimentation.

Methodology and Results

89 90

91

92

93

94

95

96

97

98

99 100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

Algorithms for Early Detection

<u>Sequence Prevalence Dynamics</u> - The BV-BRC team has developed the *SARS-CoV-2 Early Detection and Analysis Pipeline* to offer informatics support for analyzing emerging SARS-CoV-2 variants from genomic sequencing data and associated epidemiological metadata processed from public databases. Throughout the pandemic, the team has run this pipeline nearly every week to process SARS-CoV-2 genomic sequencing and epidemiological data and support the Early Detection component of the NIAID SAVE program. Data for this pipeline can be downloaded from the EpiCov portal of GISAID²⁰, NCBI GenBank, Virus Pathogen Resource²³,

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

or BV-BRC²⁴ databases. A primary aspect of this pipeline is the ability to capture four sequence prevalence dynamics segregated by month and geographic location: 1) the total SARS-CoV-2 genome sequence counts, 2) the genome sequence counts for specific lineages and variants, 3) the sequence prevalence of these lineages and variants, and 4) the growth rates of these lineages and variants from month to month (see **Supplementary Material** for more details). These sequence prevalence dynamics are calculated for individual PANGO lineages²¹, single amino acid substitutions found in any SARS-CoV-2 protein, and unique constellations of protein substitutions denoted as "covariates", which we refer to collectively as "variants". Note that covariates consist of a string of single amino acid mutations identified in one or more proteins of some SARS-CoV-2 sequence isolate. Each covariate also belongs to a specific PANGO lineage based on the nomenclature status of the origin sequence. Multiple covariates of a single protein can belong to the same PANGO lineage. In this work, we focus on the analysis of Spike covariates since this has been the initial focus of the NIAID SAVE program. Generating the sequence prevalence dynamics of emerging variants provides the required epidemiological parameters needed by the scoring heuristics for predicting which variants might be of concern. We designed a workflow to capture these dynamics as an upstream component of the scoring heuristics. Capturing the Dynamics of Emerging Variants - A custom built pipeline was routinely used to compute sequence prevalence dynamics by capturing SARS-CoV-2 variants and isolation metadata (geographic location and date of isolation) from the genomic sequencing databases. Strict quality control criteria were used to filter out genomes with high numbers of ambiguous or indeterminate bases (n>x), low sequence length coverage (n<x,000kb), missing viral names, or improper metadata such as incorrect representation of dates or region names. Genomes were then pairwise aligned to the Wuhan-Hu-1 reference genome (NC 045512.2), and a constellation of variants was extracted for the Spike protein, or for the entire SARS-CoV-2 proteome (all 16) non-structural proteins as well as E, M, N, S, ORF3a, ORF6, ORF7a, ORF7b, ORF8, ORF9b, ORF10, and ORF14). Variant constellations can then be partitioned into temporal and geographic groups. The total number of genomes isolated for these groups is also calculated and serves as the denominator for the prevalence ratio (formula 1). Dates were then partitioned by month, and variant constellation counts and total isolate counts per region per date month were used to compute epidemiological dynamics, namely the prevalence and growth rates of variants by month as shown in formulas (1) and (2).

154 (2) Growth Rate = $\frac{Prevalence\ Ratio\ in\ Region\ R\ during\ Period\ P}{Prevalence\ Ratio\ in\ Region\ R\ during\ Period\ P-1}$ 155 156 Running this process to identify variant constellations and acquire region-date counts directly 157 from the raw sequence data is a very computationally expensive task for a large batch of 158 genomes and requires High-Performance Computing. An alternative approach is to use 159 preprocessed data provided in GISAID metadata files, which can be downloaded with a 160 registered GISAID account. Records include variant constellations, geographic location, date of 161 collection, and basic quality control data such as the sequence length and ambiguous 162 nucleotide content. These files can be used to extract the Spike variant constellation of each 163 record, count the occurrence of these Spike variants by region and date, bin the dates by 164 month, and compute the monthly prevalence and growth rate dynamics for each Spike variant 165 based on the total sequence record counts per region and date. PANGO lineage designations 166 can also be used to count the occurrence of specific lineages by region and date and compute 167 spatiotemporal dynamics. A similar strategy can be used to collect data for single amino acid 168 substitutions rather than variant constellations or PANGO Lineages, iterating through each 169 sequence record, and counting the occurrence of each single mutation by region and date and 170 then computing the prevalence and growth rates of these single mutations by month per region. 171 This workflow was used to generate sequence prevalence dynamics based on either GISAID 172 metadata files or GenBank/BV-BRC FASTA files and then fed into the scoring heuristics 173 component of the pipeline (see the **Supplementary Material** for more details). 174 Sequence Prevalence Score - To identify SARS-CoV-2 variations with concerning 175 epidemiological dynamics, a scoring heuristic based on sequence prevalence ratio (Formula 1), 176 growth in sequence prevalence (Formula 2), and geographic spread was devised - the 177 Sequence Prevalence Score. This scoring method can be applied to rank variants within the 178 entire dataset, within a specific PANGO lineage, a specific WHO clade, or a user supplied list of 179 covariates. First, this method segregates variants for each country. Next, only variants with a 180 sequence count greater than 10 in the most recent month are retained to control for large 181 apparent growth rates associated with small numbers. Any variants that were filtered out are 182 assigned a score of 0. To calculate the Sequence Prevalence Score, the most recent three 183 months of data are used. A score of 1 is assigned for every country/month combination in which 184 the sequence prevalence is >5% or the growth rate from the previous month is >5-fold. These 185 numbers are then summed to obtain the final Sequence Prevalence Score across all 186 countries/month combinations. Three months of data is the default interval applied, but users

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216217

218

219

can specify this parameter through a "--interval" argument. Figure 1 shows a ranking using the Sequence Prevalence Score to prioritize variants from GISAID data processed in November of 2021, which is considered the initial month of emergence of the Omicron variant. In this ranking, the Sequence Prevalence Score for the Omicron variant is still relatively small but detectable. Functional Impact Score – While the Sequence Prevalence Score quantifies prevalence properties of variants, it requires some minimum time period to observe concerning trends and may not rank concerning variants high at early stages of emergence. A complementary approach for analyzing emerging variants independent of epidemiological dynamics is to predict their functional impact using prior knowledge from experimental datasets. We have designated regions of the Spike protein that have been experimentally shown to impact immune escape, receptor binding affinity, or viral replication as "Sequence Features of Concern" (SFoC). We detail our procedure for selecting SFoCs in the following section, but overall, these SFoCs include sites that could impact the binding of one or more monoclonal antibody classes¹⁰. neutralization with infection or vaccine (mrna-1273) induced antibodies, affect receptor binding affinity, or functionally important sites (NTD Supersite¹³, Furin Cleavage Site^{28,29}, or D614G¹⁶). Upon establishing our list of SFoCs, we assign each Spike variant a Functional Impact Score based on positional overlap with these critical regions. For each mutated position in the variant, if an overlap is found with one of the regions in the SFoC list, a score of 1 is assigned treating separately each of the monoclonal antibody classes, convalescent serum, vaccine serum, ACE2 binding affinity, NTD supersite, furin cleavage site, and site D614G. Any amino acid substitution or deletion that has a position falling within an SFoC is treated as one scorable mutation. Summing all the scores of each position mutated in the variant produces the Functional Impact Score. In Figure 2 we provide a visual representation of what this positional overlap with SFoCs defined by deep mutational scanning antibody escape data would look like. The figure comes from an implementation of these annotations in the genome browser of the BV-BRC SARS-CoV-2 Variant Tracker²⁴ and quantifies impact of monoclonal antibody binding by class for a mutation at each site on the Receptor Binding Domain. Sequence Features of Concern - Most of the data used to define the SFoCs were derived from the deep mutational scanning experiments conducted by the Bloom Lab^{2,3,4,5,6,7,8,9}. The resulting experimental data quantified the mutation impact towards monoclonal antibody escape, convalescent serum antibody escape, vaccine (mrna-1273) elicited antibody escape, and ACE2 binding affinity for nearly every position on the Receptor Binding Domain (RBD). To achieve

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

these quantifications, the Bloom Lab constructed an RBD mutant library such that each amino acid site on the RBD was mutated with the 19 possible amino acid substitutions in the genetic background of the Wuhan-Hu-1 reference strain. The Bloom Lab used rigorous statistical processing to calculate an "escape fraction" for antibody escape (all between 0 and 1) and "binding average" for ACE2 affinity (all between -5 and 1) for every mutation at every position of the RBD. Each of the different monoclonal antibodies belonging to one of the four Barnes et al. structural epitope classes¹⁰, subject specific convalescent sera, and subject specific vaccine sera had their own escape fraction scores per mutation per site. The data from all these deep mutational scanning studies can be downloaded and explored at https://jbloomlab.github.io/SARS2 RBD Ab escape maps/... We examined the distribution of scores for each antibody escape datasets and the ACE2 binding dataset to narrow down on positions of the RBD vulnerable to significant increase in antibody escape or ACE2 binding affinity upon mutation. With a consolidated violin plot for all monoclonal antibodies and convalescent/vaccine sera, the analysis of antibody escape data showed that most of the escape fraction values were close to the 0 baseline and less than 0.2 (Figure 3). Therefore, to capture positions on the RBD that lead to strong antibody escape upon being mutated, an escape fraction threshold of 0.25 was applied. Consequentially, the antibody escape SFoCs were defined as RBD sites with one or more mutations that lead to an escape fraction exceeding this threshold for some monoclonal antibody, convalescent subject sera, or vaccine subject sera. The monoclonal antibodies corresponding to a mutation exceeding this escape fraction threshold were categorized into their structural epitope class to generalize the scoring for functional impact. As a result of this threshold, we designated 75 sites on the RBD that could significantly impact the binding of up to four antibody classes and 36 sites that could significantly impact the binding of antibodies from convalescent or vaccine sera. Similarly, we evaluated the distribution of scores for the ACE2 binding affinity dataset. This analysis showed that most scores were close to the 0 baseline or negative, where a negative score implied a decrease in binding affinity (Figure 4). To identify mutations that led to increased ACE2 binding affinity, a binding average threshold of 0.1 was selected. As a result, each site with one or more mutations that exceeded this threshold was defined as an SFoC for increased ACE2 affinity, thus designating 12 sites that could significantly increase the binding to ACE2 upon mutation. We found site 501 to be included in this list, which is a notable site that leads to high degree of conformational alterations of the Spike RBD when bound to ACE2 upon acquiring a mutation³⁹.

254

255256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

The remaining Sequence Features of Concern were those deemed critical for adaptive immunity or viral tropism, such as the NTD supersites 13 (sites 14-20, 140-158, 245-264), site 614 of the Spike¹⁶, and the region flanking the furin cleavage site^{28,29} (sites 671-692). These were determined through literature curation. Composite Score - Once the Sequence Prevalence Score and the Functional Impact Score have been computed, the two are summed to produce the Composite Score, which is used in our monthly reports to NIAID SAVE for variant rankings. Composite Scoring can be applied to all variants in a dataset, variants among a specified WHO clade, covariates among a specified PANGO lineage, or variants in a user supplied list. Thus, the Composite Score can simultaneously identify variants with alarming sequence prevalence dynamics and variants that would be predicted to impact important functional characteristics of the virus or both. For example, an initial analysis of the Omicron variant using epidemiological data from November 2021 did not show a high Sequence Prevalence Score (Figure 1), but the original Omicron sequence did show a very high Functional Impact Score and therefore a high Composite Score (**Figure 5**). These results highlight the importance of paying attention to both the *Sequence* Prevalence Score and Functional Impact Score for the early identification of Variants of Interest for further evaluation. The Composite Score is also very useful in quantifying subtle differences among covariates of the same clade. By January 2022, the most dominant lineage of Omicron clade was BA.1, which included several sub-lineages with varying Spike covariates, most significantly the addition of the R346K mutation. At the same time, BA.2 was also emerging and there was a primary variant constellation similar to BA.1 but with several unique mutation sites. When a list of these distinct Omicron covariates was supplied to the ranking algorithm, differences between the original BA.1 covariate and BA.1 + R346K could be observed through an increase in the functional impact score (Figure 6). In contrast, many of the other covariates had a Sequence Prevalence Score of 0, which indicated that those covariates were not displaying any significant regional growth and likely not as threatening as the original BA.1 or the BA.1 + R346K (now known as BA.1.1) covariates. Mutation Prevalence Score – In addition to the covariate constellation analysis, a Mutation Prevalence Score analyzing single amino acid substitutions on the SARS-CoV-2 Spike protein is also calculated. As with the Sequence Prevalence Score, this approach uses data from the past three months to assign a score of 1 for every country/month combination in which the prevalence of an amino acid mutation is >5% or the growth rate is greater than 5-fold. Figure

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

7A-B show the results of ranking mutations within the RBD and NTD using global GISAID sequence data from December 2021. Emerging Lineage Score – In some cases, researchers may just want to know how the various PANGO Lineage designations differ in terms of their epidemiological dynamics. As we saw with Delta, there were a multitude of AY.* lineages for the entire WHO clade designated in a relatively short time frame, so ranking these lineages would be helpful to identify which should be prioritized for further analysis. As with the Sequence Prevalence Score, the Emerging Lineage Score begins by filtering for covariates with an assigned country and with a variant count greater than 10 in the most recent month. From there, using the past three months of data, for each PANGO lineage, every unique covariant/country/month combination in which the growth rate is greater than 15 is assigned a score of 1; these values are summed to compute the *Emerging Lineage Score*. Since this algorithm is counting multiple distinct covariates comprising each lineage, it could be biased towards PANGO lineages with very abundant covariates; hence, we used a higher growth rate threshold to capture the key covariates driving the overall growth of the lineage. A growth rate of 15 was chosen as it results in a relatively stable list of PANGO lineages. Growth rates above 15 did not significantly affect the ranking of the list. This growth rate is also appealing in that it is relatively high and therefore relatively stringent. Figure 8A-B shows the results from this method using GISAID data from December 2021 and January 2022 to rank lineages globally. BA.1 was the dominant Omicron lineage in December 2021 and was the lineage with the highest *Emerging Lineage Score*. (**Figure 8A**). However, by January 2022 additional Omicron lineages were rapidly growing with the presence of BA.1.1 and BA.2 (Figure **8B**). Since these lineages are made up of multiple covariates, we could take the results returned from the Emerging Lineage Score to decide which covariates within these lineages warranted further investigation by running a PANGO lineage specific Composite Score ranking to prioritize the covariates within a specific lineage, as shown in Figure 9 with BA.2, which captured a single covariate of the lineage with the strongest dynamics as early as January 2022. **Visualizing Early Detection** To complement our early detection analysis of emerging SARS-CoV-2 variants through our scoring and ranking algorithms, we found it useful to visualize variant growth both globally and

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

regionally to further understand the dynamics of these variants and facilitate early detection. We demonstrate the utility of these visualizations for early detection purposes by providing some case studies regarding the early dynamics of the Delta and Omicron variants. Visualizing Relative Growth of PANGO Lineages – When a new variant displays alarming epidemiological dynamics or predicted functional changes, like Delta and Omicron did, researchers may want to visualize the growth dynamics of the new variant in the context of how the prevalence of other variants are changing. We commonly see during viral evolution that when a new dominant variant/strain emerges, it triggers a phenomenon where the growth of the currently circulating variants suddenly begin to sharply decline, perhaps because the new variant has a fitness advantage and is able to outcompete the older variants 16,19,31,33. If we observe that the prevalence of a novel variant with alarming characteristics is increasing with a corresponding sudden decline in growth of other circulating variants, this will further indicate the early detection of a potential Variant of Concern. As an example, prior to the emergence of Delta, B.1.1.7-derived Alpha variants were the most dominantly circulating variants around the world. However, between May and June of 2021, it was becoming clear that the newly emerging Delta variant was displaying noteworthy properties¹⁹ and very quickly replacing the other circulating variants, including B.1.1.7 (Alpha), both globally (Figure 10A) and regionally. especially in the UK (Figure 10B). By visualizing these dynamics in stacked line plots, the relative magnitude by which a novel variant is growing offers further evidence of the early detection of a potential Variant of Concern. Visualizing Growth of Variants – In addition to tracking the emergence and growth of new PANGO lineages, it is also useful to visualize the evolution and growth of variants within the lineage. As discussed earlier, B.1.1.529 (Omicron) started to show rapid growth in December 2021 and then quickly accumulated additional substitutions, ultimately generating the newly designated BA.1 and BA.2 lineages and sub-lineages. By providing a list of covariates of interest, like the one used in Figure 6, our pipelines produced a graph showing the prevalence of a selected list (Figure 11). Comparing the Composite Score results from Figure 6 with the visualization in Figure 11, some interesting insights about BA.1 + R346K emerge. BA.1 + R346K had a high functional impact score, and while the Sequence Prevalence Score was also high, it wasn't quite as high as BA.1 for the month of January 2022. However, the Figure 11 visualization shows that BA.1 + R346K was exhibiting a sharper change in its global prevalence relative to BA.1, suggesting that this variant would warrant further monitoring. Indeed, these

plots provide a complementary representation to the *Composite Score* ranking to facilitate early detection analysis and more confidently identify variants that warrant experimental evaluation. *Visualizing Growth of Individual Amino Acid Substitutions* – Analysis of the characteristics of lineages and covariates also provided some insights into the different amino acid mutations that contribute to the multitude of covariates, in some cases from different lineages, perhaps due to convergent evolution or recombination. To assess their individual effects, the dynamics of selected single amino acid substitutions can also be plotted. For example, prior to January 2022, the L24-, R346K, N440K, G446S, L452R, A701V mutations were appearing sporadically throughout our ranked covariates. Plotting the dynamics of these individual amino acid mutations over subsequent time periods shows that the R346K and G446S mutations started to decrease in prevalence at the same time as the prevalence of L24- was rapidly increasing, suggesting that viruses carrying this mutation may possess a fitness advantage (**Figure 12**). Indeed, this L24- is part of an extended deletion that distinguishes BA.2, which subsequently replaced BA.1.

Challenges

Defining SARS-CoV-2 variants that warrant experimental evaluation for functional testing presents significant challenges. Early genomic sequencing data is often subject to data imbalances or biases with respect to specific geographic regions. Wealthier countries with higher sequencing capacity, such as the US and UK, are responsible for the majority of publicly deposited SARS-CoV-2 genomes. Of the 4.5 million SARS-CoV-2 genomes available in GenBank and BV-BRC as of April 2022, roughly 47% were from the US and 38% from the UK. Another challenge is the sequence ambiguity that can occur as a new variant emerges and before the sequencing assays can be optimized. And since the SARS-CoV-2 genomes submitted to the public databases have already been assembled, the quality of the read level data cannot be easily evaluated independently. Processing variant data through the GISAID metadata file downloads, many sequences appeared to have reverted to ancestral residues in comparison to the original Omicron outbreak sequences, but in many cases this is due to low sequence coverage in certain genomic regions that is not apparent in the metadata file. Indeed, processing assembled GenBank sequencing data from BV-BRC, only about 25% of sequences had little to no ambiguities, and the amount of ambiguity in the sequencing data fluctuated

during the initial emergence of certain important variants, like Delta and Omicron, making it challenging to compute true sequence prevalence of authentic covariates. Another challenge is choosing the amount of data that ought to be regularly downloaded for computing the early detection scoring heuristics. While focusing on the most recent data could potentially be used to identify concerning variants more swiftly, a potential drawback would be sequence biases resulting in minimal representation. On the other hand, longer temporal data is more comprehensive and accurate, but could delay identification of newly emerging variants of concern. In our pipeline, we allow the option to choose anywhere from the past 2 – 6 months of global sequencing data to evaluate, with a default of 3 as our best attempt to set a balance between early detection and unbiased, accurate results. Finally, the most enduring challenge is the fact that these data are very large and continuously growing, as new SARS-CoV-2 sequencing data are being deposited by the thousands every day. Designing pipelines to carryout real-time genomics analysis for a shear amount of data is a technically challenging task, and our techniques on how best to manage, analyze, and scale will need to continuously adapt.

Discussion

Over two and a half years since the initial declaration of the COVID-19 pandemic, it seems clear that SARS-CoV-2 will persist in our community and remain a public health issue for the indefinite future. However, if we, as a biomedical community, come together and maximize our resources to combat this virus, we can consistently minimize the threat it brings to our world and transition to a phase in which SARS-CoV-2 becomes an endemic infection with only modest effects on public health. A major factor that could contribute to consistently minimizing the threat brought by SARS-CoV-2, or any other emerging pathogen, is through genomic surveillance. Our most precise approach to monitoring viral evolution to ensure that we maintain reliable therapeutics and accurate diagnostics is by routinely collecting samples from infected individuals and using sequencing technologies to acquire the whole genome sequences. With the COVID-19 outbreak, the research and public health communities have truly excelled at this task, as we have now reached a point where millions of SARS-CoV-2 genome sequences have been deposited in public databases. That being said, all of these data are only as powerful as the computational resources used to analyze them. Thus, this

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438439

440

441

442

443

444

445

446

explosion in publicly available viral genomes also calls for the development of appropriate computational frameworks that can process and scale as the data grows to enable the timely identification and prioritization of emerging variants. In this work, we present approaches to process SARS-CoV-2 genomic sequences along with epidemiological metadata on a regular basis and apply scoring heuristics to prioritize variants based on their epidemiological dynamics and predicted functional characteristics by computing Sequence Prevalence, Functional Impact, and the Composite Scores. The output provides concise lists of ranked variant constellations (covariates), offering a straightforward approach for wet-lab scientists to immediately determine which combinations of mutations ought to be evaluated experimentally. These methods were validated through the detection of the Omicron variant and provided a relatively high-ranking score at early stages of emergence in November 2021. In addition to early detection of novel variants like Omicron, our system makes it easy to evaluate the subtle differences among the multitude of covariates arising from a single lineage, like comparing the BA.1 + R346K covariate to the original BA.1 covariate. Finally, we also provide multiple visualization methods for variant growth either by PANGO lineage, covariate, or single amino acid substitution and demonstrate how coupling rankings with visualizations can further ground our confidence in early detection of variants that warrant experimental evaluation. While the initial focus of this work was on Spike protein variants, as that was NIAID SAVE's interest for evaluation, the framework was recently extended to score and rank proteome-wide SARS-CoV-2 variant constellations and single amino acid substitutions, which we provide in our publicly available pipeline. While the primary focus was the Spike protein due to its critical role in adaptive immunity and viral tropism, the community is beginning to take serious interest in mutations arising in non-structural proteins, particularly nsp3, nsp5, and RNA-dependent RNA Polymerase (nsp12), due to their importance in the SARS-CoV-2 replication cycle and antiviral drug targeting^{34,35,36,37,38}. We are paying close attention to the literature to monitor the science behind non-Spike protein regions that play key roles in replication or impact drug targeting, and are continually updating our Sequence Features of Concern to account for this new knowledge. Ultimately, our framework can begin providing Composite Scores for a variant constellation specific to any SARS-CoV-2 protein. The methods presented in this work could be extended for evaluating variants of other viral species if sufficient data granularity is available. This approach requires enough genomic sequencing data, consistent spatiotemporal isolation metadata, a methodology to compute variants with respect to a reference or a consensus genome²², and sufficient prior knowledge

through experimental data to define Sequence Features of Concern and quantify functional impacts. Moreover, these algorithms could be extended to evaluate genomic surveillance data from zoonotic disease reservoirs, such as influenza virus in avian or swine species. Indeed, several projects already exist to collect viral genomic sequences from such reservoirs and warehouse these data in public databases¹⁸. Overall, the methodologies described here can play an important role in a complete public health ecosystem by utilizing genomic sequencing data to monitor viral evolution and remain steps ahead of SARS-CoV-2, or any other virus, and ultimately deter the next pandemic.

Data Availability Statement

Publicly available datasets were analyzed in this work, and the original contributions presented are included in the article/**Supplementary Material**. Further inquiries can be directed to the corresponding author.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author Contributions

ZSW conceptualized the methods, collected/analyzed data, developed the public version of the pipeline, and wrote the original draft of the manuscript. JD, RDO, RS, and MS conceptualized the methods and contributed to pipeline development. AN, YZ and CMZ conceptualized the methods and reviewed and edited the manuscript. RHS was the principal investigator who conceived the project, conceptualized the methods, supervised the project, acquired funding, and reviewed and edited the manuscript.

Funding This work has been funded with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services - HHS75N93019C00076. **Acknowledgements** We acknowledge the Bloom Lab at Fred Hutchinson Cancer Research Center for their advice and data sharing, the Korber Lab at Los Alamos National Laboratory for their advice on methodology, Fritz Orbermeyer/Lemieux Lab at the Broad Institute for code sharing, the San Diego Supercomputer Center/XSEDE for the allocation of the Expanse compute resources, and both the originating and submitting laboratories for the sequence data deposited in INSDC and GISAID databases. The project has benefited from the ongoing discussion among the computational biologists and experimentalists in the NIAID SAVE consortium and among the analysts and developers of the BV-BRC. **Supplementary Material** The BV-BRC SARS-CoV-2 Early Detection and Analysis Pipeline, the list of Sequence Features of Concern, and a more detailed version of the algorithms along with pseudocode are available from https://github.com/zwallace425/SARS-CoV-2 Pipeline.

References

505

526

527

528

529

530

531

535

536

- 506 (1) DeGrace, M.M et al. Defining the risk of SARS-CoV-2 variants on immune protection.
 507 *Nature*. 2022. https://doi.org/10.1038/s41586-022-04690-5
- 508 (2) Dong, J., Zost, S.J., Greaney, A.J. *et al.* Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. *Nat Microbiol* 6, 1233–1244 (2021). https://doi.org/10.1038/s41564-021-00972-2
- (3) Allison J. Greaney, Tyler N. Starr, Pavlo Gilchuk, et al. Complete Mapping of Mutations
 to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition,
 Cell Host & Microbe, Volume 2, Issue 1, 2021, Pages 44-57.e9, ISSN 1931-3128.
 https://doi.org/10.1016/j.chom.2020.11.007
- (4) Greaney, A.J., Starr, T.N., Barnes, C.O. et al. Mapping mutations to the SARS-CoV-2
 RBD that escape binding by different classes of antibodies. Nat Commun 12, 4196
 (2021). https://doi.org/10.1038/s41467-021-24435-8
- 518 (5) Allison J. Greaney, Andrea N. Loe, Lauren E. Gentle, *et al.* Antibodies elicited by mRNA-519 1273 vaccination bind more broadly to the receptor binding domain than do those from 520 SARS-CoV-2 infection. 2021. Science Translational Medicine, 13, 60. 521 https://www.science.org/doi/abs/10.1126/scitranslmed.abi9915
- 522 (6) Tyler N. Starr, Allison J. Greaney, Adam S. Dingens, Jesse D. Bloom. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Reports Medicine. Volume 2, Issue 4. 2021. 100255.

 1SSN 2666-3791. https://doi.org/10.1016/j.xcrm.2021.100255
 - (7) Starr, T.N., Czudnochowski, N., Liu, Z. et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature 597, 97–102 (2021). https://doi.org/10.1038/s41586-021-03807-6
 - (8) Tyler N. Starr, Allison J. Greaney, Amin Addetia, *et al.* Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. 2021. Science, 850-854, 371, 6531. https://www.science.org/doi/abs/10.1126/science.abf9302
- 532 (9) Tortorici, M.A., Czudnochowski, N., Starr, T.N. *et al.* Broad sarbecovirus neutralization 533 by a human monoclonal antibody. *Nature* 597, 103–108 (2021). 534 https://doi.org/10.1038/s41586-021-03817-4
 - (10) Barnes, C.O., Jette, C.A., Abernathy, M.E. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. *Nature* 588, 682–687 (2020). https://doi.org/10.1038/s41586-020-2852-1

538 (11) Matteo Chiara, Anna Maria D'Erchia, Carmela Gissi, *et al.*, Next generation 539 sequencing of SARS-CoV-2 genomes: challenges, applications and 540 opportunities, *Briefings in Bioinformatics*, Volume 22, Issue 2, March 2021, Pages 616– 541 630. https://doi.org/10.1093/bib/bbaa297

- (12) Deng, X., Achari, A., Federman, S. *et al.* Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance. *Nat Microbiol* 5, 443–454 (2020). https://doi.org/10.1038/s41564-019-0637-9
- (13) Matthew McCallum, Anna De Marco, Florian A. Lempp, et al., N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell, Volume 184, Issue 9, 2021, Pages 2332-2347.e16, SSN 0092-8674. https://doi.org/10.1016/j.cell.2021.03.028
 - (14) Benjamin L. Sievers, Saborni Chakraborty, Yong Xue, *et al.* Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. 2022. Science Translational Medicine, eabn7842, 14. 634, https://www.science.org/doi/abs/10.1126/scitranslmed
 - (15) Obermeyer, Fritz, Jankowiak, Martin, Barkas, Nikolaos, et al., Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness. medRxiv. 2022. https://doi.org/10.1101/2021.09.07.21263228
 - (16) Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020 Aug 20;182(4):812-827.e19. Epub 2020 Jul 3. PMID: 32697968; PMCID: PMC7332439. https://doi.org/10.1016/j.cell.2020.06.043
 - (17) Maher MC, Bartha I, Weaver S, di Iulio J, Ferri E, Soriaga L, et al. Predicting the mutational drivers of future SARS-CoV-2 variants of concern. Sci Transl Med. 2022 Feb 23;14(633):eabk3445. Epub 2022 Feb 23. PMID: 35014856; PMCID: PMC8939770. https://doi.org/10.1126/scitranslmed.abk3445
 - (18) Tavis K Anderson, Blake Inderski, Diego G Diel, *et al.* The United States Swine Pathogen Database: integrating veterinary diagnostic laboratory sequence data to monitor emerging pathogens of swine, *Database*, Volume 2021, 2021, baab078. https://doi.org/10.1093/database/baab078
- (19) McCrone JT, Hill V, Bajaj S, et al. Context-specific emergence and growth of the SARS-CoV-2 Delta variant. medRxiv [Preprint]. 2021 Dec 21:2021.12.14.21267606. PMID: 34981069; PMCID: PMC8722612. https://doi.org/10.1101/2021.12.14.21267606

- 571 (20) Khare, S., et al (2021) GISAID's Role in Pandemic Response. *China CDC*572 *Weekly*, 3(49): 1049-1051. PMCID: 8668406. https://doi.org/10.46234/ccdcw2021.255
- 573 (21) Rambaut, A., Holmes, E.C., O'Toole, Á. *et al.* A dynamic nomenclature proposal 574 for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol* 5, 1403–1407 575 (2020). https://doi.org/10.1038/s41564-020-0770-5
 - (22) Zhang Y, Aevermann BD, Anderson TK, et al. Influenza Research Database: An integrated bioinformatics resource for influenza virus research. Nucleic Acids Res. 2017 Jan 4;45(D1):D466-D474. Epub 2016 Sep 26. PMID: 27679478; PMCID: PMC5210613. https://doi.org/10.1093/nar/gkw857
 - (23) Pickett BE, Sadat EL, Zhang Y, et al. ViPR: an open bioinformatics database and analysis resource for virology research. *Nucleic Acids Res.* 2012;40(Database issue):D593-D598. https://doi:10.1093/nar/gkr859
 - (24) The Bacterial and Viral Bioinformatics Resource Center (BV-BRC). https://www.bv-brc.org/

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

597

- (25) Derek W Wright, William T Harvey, Joseph Hughes, *et al.* Tracking SARS-CoV-2 mutations and variants through the COG-UK-Mutation Explorer, *Virus Evolution*, Volume 8, Issue 1, 2022, veac023. https://doi.org/10.1093/ve/veac023
- (26) Harvey, W.T., Carabelli, A.M., Jackson, B. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 19, 409–424 (2021). https://doi.org/10.1038/s41579-021-00573-0
- (27) Centers for Disease Control and Prevention, SARS-CoV-2 Variants of Concern; www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html
- 594 (28) Escalera, A. et al. Mutations in SARS-CoV-2 variants of concern link to increased 595 spike cleavage and virus transmission. Cell Host Microbe. 2022. 30, 373–387.e7. 596 https://doi.org/10.1016/j.chom.2022.01.006
 - (29) Liu, Y. et al. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. Preprint at bioRxiv. 2021. https://doi.org/10.1101/2021.08.12.456173
- (30) Planas, D., Saunders, N., Maes, P. *et al.* Considerable escape of SARS-CoV-2
 Omicron to antibody neutralization. *Nature* **602**, 671–675 (2022).
 https://doi.org/10.1038/s41586-021-04389-z
- 602 (31) Martin DP, Weaver S, Tegally H *et al.* The emergence and ongoing convergent 603 evolution of the SARS-CoV-2 N501Y lineages. Cell. 2021 Sep 30;184(20):5189-5200.e7.

604 Epub 2021 Sep 7. PMID: 34537136: PMCID: PMC8421097. 605 https://doi.org/10.1016/j.cell.2021.09.003 606 (32)Starr TN, Greaney AJ, Hilton SK, et al. Deep Mutational Scanning of SARS-CoV-607 2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell. 608 2020 Sep 3;182(5):1295-1310.e20. Epub 2020 Aug 11. PMID: 32841599; PMCID: 609 PMC7418704. https://doi.org/10.1016/j.cell.2020.08.012 610 (33)Bin Zhou, Tran Thi Nhu Thao, Donata Hoffmann, et al. SARS-CoV-2 spike 611 D614G change enhances replication and transmission. *Nature*, 2021. 612 https://doi.org/10.1038/s41586-021-03361-1 613 (34)Yuyong Zhou, Karen Anbro Gammeltoft, Line Abildgaard Ryberg, et al. 614 Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in Vitro 615 bioRxiv 2022.06.06.494921; doi: https://doi.org/10.1101/2022.06.06.494921 616 (35)Dirk Jochmans, Cheng Liu, Kim Donckers, et al. The substitutions L50F, E166A 617 and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and 618 confer resistance to nirmatrelvir bioRxiv 2022.06.07.495116. 619 https://doi.org/10.1101/2022.06.07.495116 620 (36)Martin Martinot, Aude Jary, Samira Fafi-Kremer, et al. Emerging RNA-Dependent 621 RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With 622 Protracted Coronavirus Disease 2019. Clinical Infectious Diseases. Volume 73. Issue 7. 623 1 October 2021, Pages e1762-e1765. https://doi.org/10.1093/cid/ciaa1474 624 (37)Szemiel AM, Merits A, Orton RJ, et al. (2021) In vitro selection of Remdesivir 625 resistance suggests evolutionary predictability of SARS-CoV-2. PLOS Pathogens 17(9): 626 e1009929. https://doi.org/10.1371/journal.ppat.1009929 627 (38)Tchesnokov EP, Gordon CJ, Woolner E, et al. Template-dependent inhibition of 628 coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second 629 mechanism of action. J Biol Chem. 2021 Aug;297(2):101048]. 2020;295(47):16156-630 16165. https://doi.org/10.1074/jbc.AC120.015720 Gupta R. SARS-CoV-2 Omicron spike mediated immune escape and tropism 631 (39)632 shift. Res Sq [Preprint]. 2022 Jan 17. PMID: 35075452; PMCID: PMC8786230.

https://doi.org/10.21203/rs.3.rs1191837/v1

633

WHO Label	Variant	Sequence Prevalence Score
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	161
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	118
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	98
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	42
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	22
Delta	T19R,T95I,G142D,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	17
Delta	T19R,L452R,T478K,D614G,P681R,D950N	13
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R	9
Delta	T19R,G142D,L452R,T478K,D614G,P681R,D950N	9
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	8
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,G1167V	8
Delta	T19R,G142D,E156G,F157-,R158-,G181V,L452R,T478K,D614G,P681R,D950N	8
Delta	L5F,T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	7
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	6
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,D950N	6
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	6
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,Q677H,P681R,T859I,D950N	5
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,A701S,D950N,A1078S	5
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	5
Delta	T19R,G142D,E156G,F157-,R158-,A411S,L452R,T478K,D614G,P681R,D950N	5
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,I850L,D950N	5
Delta	L5F,T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	5
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,T719I,L938F,D950N	4
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,T716I,D950N	4
Delta	T19R,A67V,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	4
Delta	T19R,L244S,L452R,T478K,T572I,D614G,P681R,D950B	4
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,T572I,D614G,P681R,D950N	4
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1264L	4
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,Q613H,D614G,P681R,D950N	4
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,K1073N	4
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	4
Delta	L5F,T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,S929T,D950N	4
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,A845S,D950N,V1264L	4
Delta	L5F,T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	4
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	4
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,I850L,D950N	4
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,S680P,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	3
Delta	T19R,L244S,L452R,T478K,T572I,D614G,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	3
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,A570S,D614G,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	3
Delta	T19R,V36F,T95I,G142D,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	3
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,Q613H,D614G,P681R,D950N	3
Delta	T19R,T95I,G142D,E156G,F157-,R158-,D178N,L452R,T478K,D614G,P681R,D950N	3
Delta	T19R,T95I,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	3
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,Q677H,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,G181V,L452R,T478K,D614G,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,G161V,L452R,T478K,D614G,F681R,D550N	3
Deita		3
	A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P,S375F,K417N,	
	N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679	
Omicron	P681H,N764K,D796Y,N856K,O954H,N969K,L981F	2

Figure 1 – Global Spike Variant Ranking with the Sequence Prevalence Score. The output of a ranking based on GISAID data up to November 2021. The analysis returns a global ranking for all Spike protein variants ranked by the Sequence Prevalence Score. The initial emergence of the Omicron variant is being captured in this ranking, but at a relatively low rank, as highlighted in the table.




Figure 2 – Sequence Features of Concern from Deep Mutational Scanning Antibody Escape Data. An image from the *BV-BRC SARS-CoV-2 Variant Tracker*²⁴ genome browser shows a heatmap that quantifies the median escape fraction for each antibody class (Class 1 – 4), with the darker blue indicating greater escape fraction, implying greater antibody escape due to the mutation. We use these quantifications of potential antibody escape per mutated site per antibody class to define one type of Sequence Features of Concern. By identifying overlap between variants (bottom track) and these Sequence Features of Concern we can compute the *Functional Impact Score*.

Distribution of Antibody and Serum Escape Fractions from Deep Mutational Scanning




Figure 3 – Defining Sequence Features of Concern from a Threshold of Escape Fractions. Violin plots of the distribution of escape fraction scores for monoclonal antibody escape and serum antibody escape from the Bloom Lab deep mutational scanning data. This distribution analysis led to an escape fraction threshold cutoff of 0.25 and subsequently led to the designation of 75 RBD sites significantly impacting monoclonal antibody binding and 36 sites impacting convalescent/Moderna vaccine (mrna-1273) sera elicited antibodies upon mutation.

Distribution of ACE2 Binding Scores from Deep Mutational Scanning




Figure 4 – Defining Sequence Features of Concern from a Threshold of ACE2 Binding Scores. The distribution of ACE2 binding average scores from the Bloom Lab deep mutational scanning data. A score below 0 indicates a decrease in ACE2 binding affinity upon mutation, whereas a score above 0 indicates an increase in ACE2 affinity. Subsequently, this distribution analysis was used to select a threshold value of 0.1, that led to designating 12 RBD sites that could significantly increase ACE2 binding affinity upon mutation.

	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	161	. 10	171
Delta	TARR TOPI CAARD FARCE FART DATE LATER TATOV DELAC DERAG DOESN			
	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	118		
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	98		
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	42	9	51
	A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P,			
	S375F,K417N,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,			
Omicron	T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	2	36	38
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	22	10	32
Delta	T19R,T95I,G142D,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	17	11	28
Delta	T19R,L452R,T478K,D614G,P681R,D950N	13	7	20
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	8	10	18
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,G1167V	8	10	18
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R	9	9	18
Delta	T19R,G142D,E156G,F157-,R158-,G181V,L452R,T478K,D614G,P681R,D950N	8	10	18
Delta	T19R,G142D,L452R,T478K,D614G,P681R,D950N	9	8	17
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,Q677H,P681R,T859I,D950N	5	11	16
	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	6	10	16
	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	6	10	16
	L5F,T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	7	9	16
	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,A701S,D950N,A1078S	5	10	15
	T19R,G142D,E156G,F157-,R158-,A411S,L452R,T478K,D614G,P681R,D950N	5	10	15
	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,D950N	6		
	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,I850L,D950N	5		
	L5F,T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	5	10	15
	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,T719I,L938F,D950N	4		
	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,T716I,D950N	4	10	
	T19R,A67V,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	4		
	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,T572I,D614G,P681R,D950N	4	10	14
	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,S680P,P681R,D950N	3		
	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1264L	4	10	14
	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,Q613H,D614G,P681R,D950N	4	10	
	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	5		
	L5F,T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,S929T,D950N	4		
	T19R,G142D,F156G,F157-,R158-,L452R,T478K,D614G,P681R,A845S,D950N,V1264L	4		
	L5F,T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	4		
	T19R,V36F,T95I,G142D,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	3		
	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,Q677H,P681R,D950N	3		14
	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,K1073N	4		
	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	4	-	
	T19R,G142D,E156G,F157-,R158-,L452R,T478K,A570S,D614G,P681R,D950N	3		
	T19R,G142D,E156G,F157-,R158-,L452R,T478K,Q613H,D614G,P681R,D950N	3		
	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	4		
	T19R,T95I,G142D,E156G,F157-,R158-,D178N,L452R,T478K,D614G,P681R,D950N	3		
	T19R,F156G,F157-,R158-,L452R,T478K,D614G,P681R,I850L,D950N	4		
	T19R,T150G,F157-,R158-,L432R,T476R,D014G,F061R,I630L,D330N T19R,T95I,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	3	-	
	T19R,F156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	3		
	T19R,E156G,F157-,R158-,L452R,T476R,D614G,P681R,D950N,V1104L	3		
	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	3		
	T19R,E156G,F157-,R158-,G181V,L452R,T478K,D614G,P681R,D950N	3		
	T19R,E150G,F157-,R158-,G181V,L452R,T478R,D614G,F681R,D950B	3		
	T19R,L244S,L452R,T478K,T572I,D614G,P681R,D950N	3		
	T19R,L2445,L452R,1476R,1572I,D614G,P681R,D950N T19R,E156G,F157-,R158-,D614G,P681R,D950N	3		

Figure 5 – Global Spike Variant Ranking with the *Composite Score*. The output of a ranking based on GISAID data up to November 2021. The analysis returns a global ranking for all the Spike variants based on a *Composite Score*. In this case, the Omicron variant (highlighted in yellow) jumped considerably in rank relative to the *Sequence Prevalence Score* in **Figure 1**, thus showing the relevance of quantifying the *Functional Impact Score* in overall variant rankings.

Variant	Sequence Prevalence Score	Functional Impact Score	Composite Score
B.1.617.2 +T95I	104	10	114
B.1.1.529 (Omicron) (Now BA.1)	22	36	58
BA.1 + R346K	12	38	50
BA.1 + A701V	2	36	38
BA.1_K417_ + N440_ + G446_	7	29	36
BA.1 + I1081V	0	36	36
BA.3	0	35	35
BA.2	1	34	35
BA.1 + R346K_K417_ + N440_ + G446_	3	31	34
BA.1_K417_ + N440_ + G446_ + L452 + RA701V	0	32	32
BA.1_K417_ + N440_ + G446_ + L452R	0	32	32
BA.2_K417_ + N440_	0	30	30
BA.1_K417_ + N440_ + G446_+ I1081V	0	29	29
BA.3_K417_ + N440_ + G446_	0	28	28

Figure 6 – Global Spike Variant Ranking for a User Supplied Annotated List with the *Composite Score*. The output ranking from the *Composite Score* of an inputted list of covariates, annotated with names based on the additional or lost mutations relative to a consensus variant constellation, using GISAID data up to January 2022. These naming annotations offer simpler representations of the covariate sequence. The scoring in the last three columns quantitatively capture how these covariates differ, including the increase in functional impact for BA.1 + R346K relative to the ancestral BA.1.

(A)

RBD Rank	ing
Variant	Mutation Prevalence Score
T478K	64
L452R	34
G339D	30
E484A	26
S477N	26
S373P	25
S375F	25
Q493R	24
N501Y	23
S371L	20
Q498R	20
G496S	20
K417N	20
Y505H	19
N440K	18
G446S	18
R346K	15
S371F	2
T376A	2
R408S	2
D405N	2

(B)

NTD Rank	king
Variant	Mutation Prevalence Score
G142D	64
T95I	63
T19R	34
F157-	34
R158-	34
E156G	34
Y144-	30
V143-	30
H69-	29
V70-	29
A67V	28
Y145-	28
N211-	26
L212I	26
T19I	3
A222V	3
Y145H	3
A27S	3
V213G	2
P25-	1
L24-	1
P26-	1

Figure 7 – Global Single Amino Acid Mutation Ranking with the *Mutation Prevalence*Score. (A) The output of an RBD mutation ranking and (B) the output of an NTD mutation ranking based on GISAID data up to December 2021. The results return a ranking for Spike protein amino acid mutations ranked by the *Mutation Prevalence Score* within their respective domain, RBD or NTD.

(A)

December 2021 Ranking WHO Label PANGO Lineage Emerging Lineage Score					
Omicron	BA.1	57			
Delta	AY.43	14			
Delta	AY.122	12			
Delta	AY.4	10			
Delta	B.1.617.2	6			
Delta	AY.127	4			
Delta	AY.121	4			
Delta	AY.4.2	3			
Delta	AY.126	2			
Delta	AY.39.1	2			
Delta	AY.3	2			
Delta	AY.25	2			
Delta	AY.43.4	2			
Delta	AY.39.1.1	2			
Delta	AY.46.6	1			
Delta	AY.29	1			
Delta	AY.4.2.3	1			
Delta	AY.4.5	1			
Delta	AY.123	1			
Delta	AY.119	1			
Delta	AY.85	1			
Delta	AY.36	1			
Delta	AY.39	1			
Delta	AY.58	1			
Delta	AY.111	1			

(B)
•	,


January 2022 Ranking				
WHO Label	PANGO Lineage	Emerging Lineage Score		
Omicron	BA.1	103		
Omicron	BA.1.1	46		
Omicron	BA.2	15		
Delta	AY.122	3		
Delta	AY.4	3		
Delta	AY.69	1		
Delta	AY.43	1		
Delta	AY.39.1.1	1		
Delta	B.1.617.2	1		
Delta	AY.4.2.3	1		
Delta	AY.102	1		
Delta	AY.36	1		
Delta	AY.39.1	1		
Delta	AY.111	1		
Delta	AY.132	1		

Figure 8 – PANGO Lineage Ranking with the *Emerging Lineage Score*. The output of a lineage ranking based on GISAID data up to December 2021 (A) and January 2022 (B). The results return a global ranking of PANGO Lineages based on the *Emerging Lineage Score*. In December 2021, BA.1 was the strongest emerging lineage with other Delta sub-lineages still on the rise. However, by January 2022, several Omicron lineages were newly emerging, with the Delta lineages tapering off.

Variant	Sequence Prevalence Score	Functional Impact Score	Composite Score
T19I,L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,			
D405N,R408S,K417N,N440K,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,		24	43
D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	13	34	47
T19I,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N, N440K,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,			
P681H,N764K,D796Y,Q954H,N969K	2	34	36
T19I,L24-,P25-,P26-,A27S,G142D,G339D,S371F,S373P,S375F,T376A,D405N,R408S,			
K417N,N440K,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,			
P681H,N764K,D796Y,Q954H,N969K	2	. 34	36
T19I,L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,			
R408S,K417N,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K, P681H,N764K,D796Y,Q954H,N969K	2	33	35
T19I,L24-,P25-,P26-,A275,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,		. 55	33
K417N,N440K,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,			
N764K,D796Y,G798D,Q954H,N969K	1	. 34	35
T19I,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,S477N,T478K,			
E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	2	. 33	35
T19I,L24-,P25-,P26-,A275,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,			
N440K,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,N764K, D796Y,Q954H,N969K	1	. 33	34
T19I,L24-,P25-,P26-,A27S,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,	_	. 55	
S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,N764K,			
D796Y,Q954H,N969K	1	. 32	33
T19I,L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,			
R408S,K417N,N440K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,		. 32	33
N764K,D796Y,Q954H,N969K T19I,L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,	1	. 52	33
R408S,N440K,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,			
P681H,N764K,D796Y,Q954H,N969K	1	. 31	32
T19I,L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,			
R408S,K417N,N440K,S477N,T478K,E484A,Q493R,D614G,H655Y,N679K,P681H,			
N764K,D796Y,Q954H,N969K	1	. 25	26
T19I,L24-,P25-,P26-,A27S,G142D,V213G,S477N,T478K,E484A,Q493R,Q498R,N501Y, Y505H,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	1	. 24	25
T19I,L24-,P25-,P26-,A27S,G142D,V213G,S477N,T478K,E484A,Q493R,Q498R,N501Y,		. 24	23
Y505H,D614G,H655Y,N679K,P681H,D796Y,Q954H,N969K	1	. 24	25
T19I,L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,			
R408S,K417N,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	2	14	16
T19I,L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,		4.5	
R408S,K417N,N440K,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K T19I,L24-,P25-,P26-,A27S,G142D,G339D,S371F,S373P,S375F,T376A,D405N,	1	. 15	16
R408S,K417N,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	1	. 14	15
L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,	_		
R408S,K417N,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	1	. 13	14

Figure 9 – Global Ranking of BA.2 Variants with the *Composite Score*. The output of a *Composite Score* ranking based on GISAID data up to January 2022. The purpose of this ranking is to focus the analysis on covariates within a specific lineage, in this case within BA.2. The ability to capture a dominant covariate (top row) likely driving much of the observed dynamics for this lineage can be observed.

(A)



(B)




Figure 10 – Visualizing the Emergence of the Delta (B.1.617.2) Variant. (A) A plot of global trends overtime based on GISAID data up to June 2021 to visualize the early growth dynamics of Delta. The graph displays the 10 PANGO lineages with the most substantial global

prevalence dynamics over a six-month time frame, with the early emergence of B.1.671.2 and the sudden sharp decline of B.1.1.7 clearly evident. **(B)** A plot of growth trends for Delta in the United Kingdom based on GISAID data up to June 2021. The graph displays the PANGO lineages with the most substantial global prevalence dynamics over a six-month time frame solely within the United Kingdom and shows the local growth of B.1.617.2 and decline of B.1.1.7.

A Time Course of User Inputted Covariate Prevalence Ratios from Sequences Isolated in World




Figure 11 – Visualizing the Emergence of Omicron Variant Constellations. A plot displaying the prevalence dynamics over six months of Spike covariates in an inputted file based on GISAID data up to January 2022. This visualization captures the sharp growth and relatively large global prevalence of BA.1 + R346K. The names presented in the legend mean the ancestral PANGO lineage +/- certain amino acid mutations to represent different covariates. Underscores indicate that certain mutations were lost relative to the ancestral sequence.







Figure 12 – Visualizing Growth Patterns of Single Amino Acid Mutations in the Spike Protein. A plot based on GISAID data up to March 2022 demonstrating the shift in dynamics for individual amino acid mutations. This plot is based on an inputted list of six amino acid mutations. Note that the L24- is a part of an extended deletion that also includes P25 and P26 found in BA.2.

WHO Label	Variant	Sequence Prevalence Score
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	161
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	118
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	98
Delta me	edRxiv preprint doi: https://doi.org/10.1101/2022.08.08.22278553; this version posted August 10, 2022. The copyright holder for this preprint (which was not derived by peen duraw) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.	42
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	22
Delta	T19R,T95I,G142D,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	17
Delta	T19R,L452R,T478K,D614G,P681R,D950N	13
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R	9
Delta	T19R,G142D,L452R,T478K,D614G,P681R,D950N	9
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	8
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,G1167V	8
Delta	T19R,G142D,E156G,F157-,R158-,G181V,L452R,T478K,D614G,P681R,D950N	8
Delta	L5F,T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	7
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	6
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,D950N	6
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	6
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,Q677H,P681R,T859I,D950N	5
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,A701S,D950N,A1078S	5
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	5
Delta	T19R,G142D,E156G,F157-,R158-,A411S,L452R,T478K,D614G,P681R,D950N	5
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,I850L,D950N	5
Delta	L5F,T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	5
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,T719I,L938F,D950N	4
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,T716I,D950N	4
Delta	T19R,A67V,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	4
Delta	T19R,L244S,L452R,T478K,T572I,D614G,P681R,D950B	4
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,T572I,D614G,P681R,D950N	4
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1264L	4
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,Q613H,D614G,P681R,D950N	4
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,K1073N	4
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	4
Delta	L5F,T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,S929T,D950N	4
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,A845S,D950N,V1264L	4
Delta	L5F,T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	4
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	4
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,I850L,D950N	4
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,S680P,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	3
Delta	T19R,L244S,L452R,T478K,T572I,D614G,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	3
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,A570S,D614G,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	3
Delta	T19R,V36F,T95I,G142D,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	3
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,Q613H,D614G,P681R,D950N	3
Delta	T19R,T95I,G142D,E156G,F157-,R158-,D178N,L452R,T478K,D614G,P681R,D950N	3
Delta	T19R,T95I,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	3
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,Q677H,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,G181V,L452R,T478K,D614G,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,D614G,P681R,D950N	3
	A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P,S375F,K417N,	
	N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,	
Omicron	P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	2







WHO Label	Variant	Sequence Prevalence Score	Functional Impact Score	Composite Score
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	161	10	171
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	118	10	128
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	98	9	107
Delta me	edRxiv preprint doi; https://doi.org/10.1101/2022.08.08.22278553; this version posted August 10, 2022. The copyright holder for this (which was holder by been divisor) is the author/funder, who had granted medRxiv a license to display the preprint in perp	s preprint 42	9	51
	It is made available under a CC-BY-NC-ND 4.0 International license . A67V, H69-, V70-, T95I, G142D, V143-, Y144-, Y145-, N211-, L212I, G339D, S371L, S373P,			
	S375F,K417N,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,			
Omicron	T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	2	36	38
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	22		
Delta	T19R,T95I,G142D,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	17		
Delta	T19R,L452R,T478K,D614G,P681R,D950N	13		20
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	8	10	
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,G1167V	8	10	
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R	9	9	18
Delta	T19R,G142D,E156G,F157-,R158-,G181V,L452R,T478K,D614G,P681R,D950N	8	10	
Delta	T19R,G142D,L452R,T478K,D614G,P681R,D950N	9		17
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,Q677H,P681R,T859I,D950N	5	11	16
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	6	10	
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	6	10	
Delta	L5F,T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	7	9	16
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,A701S,D950N,A1078S	,	10	
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	5	10	
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,D950N	5	9	15
Delta		0	10	
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,I850L,D950N	5	10	
	L5F,T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	3		
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,T719I,L938F,D950N	4	10	
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,T716I,D950N	4	10	
Delta	T19R,A67V,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	4	10	
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,T572I,D614G,P681R,D950N	4	10	
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,S680P,P681R,D950N	3	11	
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1264L	4	10	
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,Q613H,D614G,P681R,D950N	4	10	
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	3	9	
Delta	L5F,T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,S929T,D950N	4	10	
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,A845S,D950N,V1264L	4	10	
Delta	L5F,T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	4	10	
Delta	T19R,V36F,T95I,G142D,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	3	11	
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,Q677H,P681R,D950N	3	11	
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,K1073N	4	9	
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	4	9	
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,A570S,D614G,P681R,D950N	3	10	
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,Q613H,D614G,P681R,D950N	3	10	
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	4	9	
Delta	T19R,T95I,G142D,E156G,F157-,R158-,D178N,L452R,T478K,D614G,P681R,D950N	3	10	
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,I850L,D950N	4	9	
Delta	T19R,T95I,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	3	10	
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	3	9	12
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	3	9	
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	3	9	
Delta	T19R,E156G,F157-,R158-,G181V,L452R,T478K,D614G,P681R,D950N	3	9	12
Delta	T19R,L244S,L452R,T478K,T572I,D614G,P681R,D950B	4	7	11
Delta	T19R,L244S,L452R,T478K,T572I,D614G,P681R,D950N	3	7	10
Delta	T19R,E156G,F157-,R158-,D614G,P681R,D950N	3	5	8

Variant	Sequence Prevalence Score	Functional Impact Score	Composite Score
B.1.617.2 +T95I	104	10	114
B.1.1.529 (Omicron) (Now BA.1)	22	36	58
BA.1 + R346K	12	38	50
BA.1 + A701V	2	36	38
BA.1_K417_ + N440_ + G446_	7	29	36
BA.1 + I1081V	0	36	36
BA.3	0	35	35
BA.2	1	34	35
BA.1 + R346K_K417_ + N440_ + G446_	3	31	34
BA.1_K417_ + N440_ + G446_ + L452 + RA701V	0	32	32
BA.1_K417_ + N440_ + G446_ + L452R	0	32	32
BA.2_K417_ + N440_	0	30	30
BA.1_K417_ + N440_ + G446_+ I1081V	0	29	29
BA.3_K417_ + N440_ + G446_	0	28	28

RBD Ranking Variant T478K L452R G339D E484A

S477N

S373P

S375F

Q493R N501Y

S371L

Q498R

G496S

K417N

Y505H

N440K

G4465

R346K

S371F

T376A

R408S

D405N

Matation Prevalence Score

64

34

30

26

26

25

25 24

23

20

20

20

20

19

18

18

15

2

2

2

NTD Ranking Variant G142D T951

T19R

F157-

R158-

E156G

Y144-

V143-

H69-

V70-

A67V

Y145-

N211-

L2121

T191

A222V

Y145H

V213G

A27S

P25-

L24-

P26-

Mutation Prevalence Score

64

63

34

34

34

34

30

30

29

29

28

28

26

26

3

3

3

3

2

1

1

December 2021 Ranking			
WHO Label	PANGO Lineage	Emerging Lineage Score	
Omicron	BA.1	57	
Delta	AY.43	14	
Delta	AY.122	12	
Delta	AY.4	10	
Delta	B.1.617.2	6	
Delta	AY.127	4	
Delta	AY.121	4	
Delta	AY.4.2	3	
Delta	AY.126	2	
Delta	AY.39.1	2	
Delta	AY.3	2	
Delta	AY.25	2	
Delta	AY.43.4	2	
Delta	AY.39.1.1	2	
Delta	AY.46.6	1	
Delta	AY.29	1	
Delta	AY.4.2.3	1	

Delta

Delta

Delta

Delta

Delta

Delta

Delta

Delta

AY.4.5

AY.123

AY.119

AY.85

AY.36

AY.39

AY.58

AY.111

1

1

1

1

1

1

1

January 2022 Ranking PANGO Lineage Emerging Lineage Score WHO Label Omicron BA.1 103 Omicron BA.1.1 46 15 Omicron BA.2 Delta AY.122 Delta AY.4 Delta AY.69 Delta AY.43 Delta AY.39.1.1 Delta B.1.617.2 Delta AY.4.2.3

Delta

Delta

Delta

Delta

Delta


AY.102


AY.39.1


AY.111 AY.132

AY.36

Variant	Sequence Prevalence Score
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P,S375F,K417N,N440K, G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H, N764K,D796Y,N856K,Q954H,N969K,L981F	74
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,R346K,S371L,S373P,S375F, K417N,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G, H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	57
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P,S375F,S477N,T478K, E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,D796Y,N856K,Q954H,N969K,L981F	16
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P,S375F,S477N,T478K, E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K, Q954H,N969K,L981F	15
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,R346K,S371L,S373P,S375F,S477N, T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y, N856K,Q954H,N969K,L981F	13
T19I,L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,N440K, S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	13
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,R346K,S371L,S373P,S375F,S477N, T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,D796Y,N856K, Q954H,N969K,L981F	12
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P,S375F,K417N, N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y, N679K,P681H,A701V,N764K,D796Y,N856K,Q954H,N969K,L981F	12
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,G339D,T547K,D614G,H655Y,N679K,P681H,N764K, D796Y,N856K,Q954H,N969K,L981F	10
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,K417N,N440K,G446S,S477N,T478K,E484A,Q493R, G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	9
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y, N856K,Q954H,N969K,L981F	9
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,G339D,R346K,S371L,S373P,S375F,K417N,N440K,G446S,S477N, T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H, N969K,L981F	9
G339D,R346K,S371L,S373P,S375F,K417N,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R, N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	8
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P,S375F,N440K,G446S, S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y, N856K,Q954H,N969K,L981F	8
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,R346K,S371L,S373P,S375F,N440K,G446S, S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y, N856K,Q954H,N969K,L981F	7
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P,S375F,K417N,N440K,G446S,S477N, T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,F643L,H655Y,N679K,P681H,A701V,N764K,D796Y, N856K,Q954H,N969K,L981F	6
A67V,T95I,G339D,S371L,S373P,S375F,K417N,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H, T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	5







A Time Course of Prevalence Ratios for User Inputted Mutations from Sequences Isolated in World — L24-— G446S --- R346K — L452R N440K 1.0 0.8 0.6 0.4 0.2 -0.0

Year and Month

202112

202201

202202

202203

Mutation Prevalence Ratio (Mutation Count/Isolates Count)

202110